First and only FDA-approved device of its kind demonstrates consistently high rates of target limb salvage and freedom from clinically-driven target lesion revascularization
Acceptance based on results from the phase 3 KEYNOTE-091 trial
Group 4 Medulloblastoma is a rare disease that mostly affects pediatric patients, in which aberrant SRC signaling was identified as a hallmark of the disease
Next-generation booster vaccine candidate demonstrates potential to protect against COVID-19 variants of concern, including Omicron BA.1 and BA.2, with a favorable safety and tolerability profile
Strides was granted a Competitive Generic Therapy (CGT) designation for its ANDA.
Amarex Clinical Research guides its client to phase II of FDA trials
Cantourage introduces second Clever Leaves medical cannabis product to the German market
Tislelizumab is now approved in nine indications in China
Centre of Excellence at Kharel comprises Skill-building Centre and Primary, Secondary and Higher Secondary schools
Dupixent is the first and only biologic medicine approved to treat moderate-to-severe atopic dermatitis from infancy to adulthood
Subscribe To Our Newsletter & Stay Updated
